HIMS — Hims & Hers Health Share News
0.000.00%
Last trade - 00:00- $6.85bn
- $7.38bn
- $2.35bn
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye
Leerink sees about $440 million peptide revenue chance for Hims & Hers
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway
U.S. STOCKS ON THE MOVE-Ollie's Bargain Outlet Holdings, Steel Dynamics
U.S. STOCKS ON THE MOVE-GameStop, Gitlab, T1 Energy
US FDA's peptide classification review could expand Hims & Hers' market share, Canaccord says
Brief: Hims & Hers Health Expands Benefits Program With Eight New Partners
U.S. STOCKS ON THE MOVE-Boston Scientific, Banc of California, Salesforce
U.S. STOCKS ON THE MOVE-UnitedHealth, Astrotech, Boston Scientific
U.S. STOCKS ON THE MOVEd-Micron, Abercrombie & Fitch, Q32 Bio
U.S. STOCKS ON THE MOVE-MGM, Hims & Hers, Semtech
Hims & Hers rises as board member boosts stake amid stock rout
BofA says Hims & Hers 2026 revenue target hinges on GLP-1 growth, lowers PT
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry (updated)
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry
U.S. STOCKS ON THE MOVE- Hims & Hers Health, Driven Brands, Onto Innovation
U.S. STOCKS ON THE MOVE-T1 Energy, Home Depot, X-Energy